Background Various randomized-controlled clinical trials (RCTs) have investigated the neuroprotective role of minocycline in acute ischemic stroke (AIS) or acute intracerebral hemorrhage (ICH) patients. We sought to consolidate and investigate the efficacy and safety of minocycline in patients with acute stroke. Methods Literature search spanned through November 30, 2017 across major databases to identify all RCTs that reported following efficacy outcomes among acute stroke patients treated with minocycline vs. placebo: National Institute of Health Stroke Scale (NIHSS), Barthel Index (BI), and modified Rankin Scale (mRS) scores. Additional safety, neuroimaging and biochemical endpoints were extracted. We pooled mean differences (MD) and risk ratios (RR) from RCTs using randomeffects models. Results We identified 7 RCTs comprising a total of 426 patients. Of these, additional unpublished data was obtained on contacting corresponding authors of 5 RCTs. In pooled analysis, minocycline demonstrated a favorable trend towards 3-month functional independence (mRS-scores of 0-2) (RR = 1.31; 95% CI 0.98-1.74, p = 0.06) and 3-month BI (MD = 6.92; 95% CI − 0.92, 14.75; p = 0.08). In AIS subgroup, minocycline was associated with higher rates of 3-month mRS-scores of 0-2 (RR = 1.59; 95% CI 1.19-2.12, p = 0.002; I 2 = 58%) and 3-month BI (MD = 12.37; 95% CI 5.60, 19.14, p = 0.0003; I 2 = 47%), whereas reduced the 3-month NIHSS (MD − 2.84; 95% CI − 5.55, − 0.13; p = 0.04; I 2 = 86%). Minocycline administration was not associated with an increased risk of mortality, recurrent stroke, myocardial infarction and hemorrhagic conversion. Conclusions Although data is limited, minocycline demonstrated efficacy and seems a promising neuroprotective agent in acute stroke patients, especially in AIS subgroup. Further RCTs are needed to evaluate the efficacy and safety of minocycline among ICH patients.
Introduction
Minocycline is a semisynthetic second-generation tetracycline that provides neuroprotective effects in various neurological disease processes [1] [2] [3] [4] . As a lipophilic agent that readily crosses the blood-brain barrier (BBB), minocycline has demonstrated improved outcomes in focal cerebral ischemia [5, 6] , and further suggested reduction in the infarct size and hemorrhagic conversion in ischemic stroke. Minocycline does not affect the fibrinolytic effects of intravenous tissue-plasminogen-activator (tPA) [7] , rendering a scope to extend the thrombolytic window in ischemic stroke patients [8] . Although the results seem to be promising, majority of the efficacy data on minocycline has involved animal studies, whereas data from human studies remain scarce.
A small number of phase II RCTs (randomized-controlled clinical trials) have investigated the efficacy of minocycline by assessing clinical recovery after acute ischemic stroke (AIS) without convincing results [9] . Recently, the efficacy and safety of minocycline administration has been analyzed in acute intracerebral hemorrhage (ICH) cohorts [10, 11] . Given the limited data available on the clinical efficacy and safety of minocycline on post-stroke functional outcomes, the objective of our systematic review and meta-analysis was to consolidate the evidence on the utilization, efficacy and safety of minocycline in ischemic and hemorrhagic strokes. We additionally analyzed the role of minocycline in reduction of hematoma and perihematomal edema (PHE) volumes among ICH patients.
Methods
Our study is reported in accordance to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, and was exempt for approval from the Institutional Review Board of our Institution. Our study protocol for inclusion and exclusion criteria was designed a priori, however, was not registered.
Data sources and searches
All the RCTs that reported and compared the neuroprotective effects of minocycline with placebo were identified by systematic search in Ovid Medline, Ovid Embase, Scopus, ClinicalTrials.gov and Google Scholar databases from database inception to November 30, 2017. The combinations of search strings used to perform our search were "stroke", "cerebrovascular disease", "cerebral ischemia", "hemorrhagic stroke", "intracerebral hemorrhage", "neuroprotection" and "minocycline". The complete search algorithm used in MEDLINE is available in the online supplement. For any missing or unpublished data, corresponding authors were contacted and individual patient-level data was obtained. We restricted our search to human studies and publications in English language. We performed an additional manual search of conference abstracts and bibliographies of articles meeting study criteria for a comprehensive literature search.
Study selection and data extraction
We identified trials that investigated clinical outcomes in patients treated with minocycline and placebo. The inclusion criteria were: (1) randomized controlled design; (2) trials comparing neuroprotective effects of minocycline vs. placebo in patients with acute stroke; (3) availability of clinical outcome data including NIHSS (National Institutes of Health Stroke Scale), mRS (modified Rankin Scale) score, BI (Barthel Index), and mortality; (4) adult patients (> 18 years old).
Two authors (KM and AK) independently reviewed all the retrieved articles. In case of disagreements regarding study inclusion or exclusion, the remaining coauthors were consulted and disagreement was resolved with mutual consensus. The following information were extracted: name of the study, first author and year of publication, mean age, sex distribution, trial name, total number and type of study participants, prevalence of cerebrovascular risk factors, stroke clinical syndrome, clinical outcomes, and follow-up duration. Clinical outcomes (mRS, BI, NIHSS scores) were studied at baseline, day 5-7, 1-month, and 3-month time periods. We further dichotomized the clinical outcomes: mRS 0-1 (favorable functional outcome), mRS 0-2 (functional independence), and mRS 6 (mortality). Our primary objective was to assess the efficacy of minocycline in regards to the clinical recovery of acute stroke patients, and further evaluate among AIS and ICH subgroups by performing sensitivity analyses. Following efficacy outcomes were analyzed: functional independence (mRS 0-2), mean NIHSS and BI scores at 3 months. We also evaluated pooled and individual efficacy outcomes based on different time intervals of clinical assessment. Our secondary objective involved the assessment of safety and neuroprotective role of minocycline among AIS and ICH patients. We additionally assessed neuroimaging and biochemical endpoints in ICH patients by analyzing the reduction of matrix metalloproteinase (MMP)-9 levels, PHE and hematoma volumes. The corresponding authors of 5 RCTs [9] [10] [11] [12] [13] were contacted and were requested by KM to contribute unpublished original data regarding primary and secondary outcomes for this meta-analysis.
Risk of bias assessment
Cochrane risk of bias assessment was used to explore the potential sources of bias among the included RCTs. This scale evaluates the following criteria: (1) Randomized sequence generation, (2) allocation concealment, (3) blinding of participants, personnel and outcome assessors, (4) incomplete outcome data, (5) selective outcome reporting, and (6) other sources of bias. Risk of bias was labeled as high, low or unclear by 2 independent investigators (KM and AK). We assessed the symmetry of funnel plots to analyze the publication bias amongst the involved trials.
Data synthesis and statistical analysis
We calculated mean difference (MD) or relative risk (RR) and their corresponding 95% confidence interval (CI) of reported outcomes between minocycline and placebo groups for each RCT, and pooled separately using the random-effects model (DerSimonian Laird) [14] . We used inverse variance method to calculate MD for continuous outcomes, and Mantel-Haenszel (M-H) method to assess the difference in risks between the treatment arms for categorical variables. For studies with a zero cell, we used a continuity correction of 0.5 [15] . The RCTs with zero events in both cells were not depicted in the final plots; however, their data was used to obtain the final pooled RR using M-H method. We additionally performed shift analysis based on 3-month mRS-scores, and the effect corresponds to common OR (cOR) in ordinal logistic regression analyses (per 1-grade improvement in mRS-scores). As per the Cochrane Handbook for Systematic Reviews of Interventions [16] , we assessed for heterogeneity using Cochran Q and I 2 statistics. For the qualitative interpretation of heterogeneity, I
2 > 50% and I 2 > 75% indicated substantial and considerable heterogeneity, respectively. Publication bias across individual studies was graphically evaluated using a funnel plot [17] , while formal assessment with Egger's test could not be performed due to small number of studies (< 10 RCTs) [18] . We performed equivalent z test for each pooled RR, and a two-tailed p values < 0.05 was considered statistically significant [14] . Sensitivity analyses were conducted separately for the subgroups of AIS and ICH. All statistical analyses were carried out with Cochrane Collaboration's Review Manager Software Package (RevMan 5.3) and the metafor package of R 3.3.2 (The R Foundation).
Results

Study selection and study characteristics
Systematic search of all the databases yielded a total of 2009 articles. After removing the duplicates, the titles and abstracts from the remaining 1122 studies were screened and 11 potentially eligible studies were retained for full-text evaluation. After retrieving the full-text version of the aforementioned 11 studies, 2 RCTs [19, 20] were excluded due to lack of comparator groups, whereas remaining 2 studies were duplicates among the 11 potentially eligible studies (Supplemental Table I ). After careful evaluation and without disagreements amongst the 2 reviewers, 7 RCTs were included that met the study protocol's inclusion criteria. The detailed study flow chart is presented in Supplemental Figure I . The corresponding authors of 5 RCTs [9] [10] [11] [12] [13] were individually contacted who contributed their original unpublished data for clinical and radiological outcomes from their respective RCTs. Table 1 summarizes the 7 RCTs comprising of 426 patients with a median follow-up of 3 months. Three RCTs were conducted in Asia, two in Australia, and the remaining two RCTs were conducted in North America. The mean values for various clinical outcomes assessed at 3-months were available from 6 RCTs for mRS-scores [9-12, 21, 22] , and 5 RCTs each for NIHSS [10, 11, 13, 21, 22] and BI [9, 10, 12, 21, 22] scores. The doses of minocycline varied from 200 mg/day in 4 RCTs, 400 mg/day in 1 RCT and 10 mg/kg/day in 1 RCT with a maximum allowed dosage up to 700 mg/day. The distribution of acute stroke subtypes across the 7 RCTs were AIS (n = 4), ICH (n = 2), AIS and ICH (n = 1). Although majority of the study cohort for Kohler and colleagues [9] comprised of AIS patients, approximately 12% of the cohort involved hemorrhagic strokes and separate clinical outcome data was not available for each subgroup of patients. The baseline characteristics (demographics and vascular risk factors) of the included studies are presented in Supplemental Table II .
Study quality and publication bias
The individual and pooled assessments of the risk of bias across included RCTs are presented in Supplemental Figure  II . Random sequence generation and allocation concealment was low in half of the included trials, while the risk was unclear in the remaining trials. All the RCTs were noted to have a high risk of performance bias due to their open-label design, while only one RCT was noted to have detectionbias. Visual inspection of the funnel plots revealed no evidence of publication bias for the outcomes of 3-month mRS (Supplemental Figure III) , 3-month NIHSS score (Supplemental Figure IV) , and 3-month BI (Supplemental Figure  V) .
Efficacy outcomes
Modified Rankin Scale score
In the pooled analysis, minocycline demonstrated a trend towards higher likelihood of functional independence 
Barthel Index score
Minocycline was associated with a higher likelihood of improved 3-month BI amongst AIS patients (3 RCTs, 242 patients; MD = 12.37; 95% CI 5.60, 19.14, p = 0.0003; p for Cochran Q statistic = 0.15, I 2 = 47%; Fig. 3) ; however, there was no beneficial effect in the ICH (1 RCT, 20 patients; MD= − 1.00; 95% CI − 11.51, 9.51, p = 0.85) or combined AIS and ICH (1 RCT, 92 patients; MD= − 1.62; 95% CI − 12.69, 9.45, p = 0.77) subgroups. Additionally, 
Safety outcomes
Mortality
In the pooled analysis, minocycline administration did not increase the risk of 3-month mortality (7 RCTs involving 426 patients; RR: 0.70; 95% CI 0.29-1.72, p = 0.44; Supplemental Figure XV ) after using the continuity correction (Supplemental Table III ). There was no evidence of heterogeneity, with an I 2 = 10% (p for Cochran Q statistic = 0.34). 
Neuroimaging and biochemical endpoints in ICH patients
Although the number of patients included in 2 RCTs involving ICH patients was low (n = 36 patients), we sought to assess the neuroprotective effect of minocycline among ICH patients by analyzing serum biomarker MMP-9 levels, and neuroimaging metrics including PHE and ICH volumes. Minocycline was not associated with a reduction of MMP-9 at days 1-3 (2 RCTs; MD 28.87; 95% CI − 57.81, 115.55, p = 0.51; p for Cochran Q statistic = 1.00, I 2 = 0%; Supplemental Figure XVIII 
Subgroup analyses
We compared the RCTs for their reported clinical outcomes based on the route of minocycline administration.
In the subgroup analysis of RCTs comparing oral and intravenous minocycline administration, oral route was significantly associated with a higher likelihood of 3-month functional independence ( 
Discussion
To the best of our knowledge, this is the first comprehensive systematic review and meta-analysis to evaluate the efficacy and safety profiles of minocycline in comparison to placebo involving acute stroke patients. Among 7 RCTs involving 426 patients, minocycline suggested a trend towards improved 3-month functional independence and BI scores. This association was significantly noted in our sensitivity analyses involving AIS patients for 3-month functional independence, BI and NIHSS scores. Additionally, minocycline was safe in both ischemic and hemorrhagic stroke patients, and was not related to increased mortality, recurrent stroke or adverse events. Finally, we observed no association of Prior human studies have investigated the efficacy of minocycline in patients with ischemic stroke. However, the results were conflicting to assess the efficacy and further stratify its neuroprotective role. Kohler and colleagues [9] performed a multicenter RCT to assess the efficacy and safety of minocycline in both ischemic and hemorrhagic stroke patients. Although the trial demonstrated that intravenous administration of minocycline is safe, its efficacy could not be established, as the study was underpowered to analyze the treatment effect of minocycline. On the contrary, three additional RCTs [13, 21, 22] have demonstrated the efficacy of minocycline among ischemic stroke patients by demonstrating the improvement in NIHSS score [13, 21, 22] , mRS score [21, 22] and BI [21, 22] . Our detailed analyses highlights the net clinical benefit of minocycline in AIS patients for early stroke recovery. With the significant clinical benefit observed with minocycline in AIS subgroup, it is reasonable to anticipate that minocycline could be routinely used for clinical recovery of AIS patients in future. Although the results are reassuring, the included trials were observed to have inherent heterogeneities amongst the comparator groups, especially in relation to the dosing, route of delivery, and therapeutic window for mincocyline. At this stage, our results likely serve for the design of future adequately powered phase III RCTs that will eventually establish potential efficacy and neuroprotective role of minocycline in AIS patients.
Minocycline is a semisynthetic antibiotic with additional neuroprotective properties. Apart from inhibition of MMP-9 levels, data suggests that minocycline has other pleiotropic properties including anti-inflammation, anti-oxidation, anti-apoptosis, vascular protection, and reduction of harmful bleeding effects from IV tPA [7, 8] . Increase in MMP-9 levels has been associated with the disruption of BBB [23] , poor functional recovery [24] , worsening of hematoma [25] and perihematomal edema [26] volumes in patients with hemorrhagic strokes. Switzer et al. have previously assessed the levels of MMP-9 in AIS patients receiving IV tPA, and corroborated these findings with a trend for reduced MMP-9 levels within an hour of minocycline infusion [19] . These findings underscore the potency of minocycline as an adjunctive therapy with IV tPA, with a potential to expand the narrow thrombolytic window period in ischemic stroke patients [7, 8] .
Recently, few studies have investigated the clinical efficacy and safety of minocycline administration in ICH patients. Chang et al. [10] conducted a pilot RCT for the assessment of MMP-9 inhibition and safety profile of minocycline in patients with acute spontaneous ICH. Although the trial was underpowered to assess for functional recovery or radiological improvement based on PHE and ICH volumes, the authors noted a trend towards reduced MMP-9 levels, especially after days 3-5 of minocycline administration. A similar trial assessed the pharmacokinetic and safety profile of minocycline in ICH patients [11] . However, due to limitations in sample size and incomplete enrollment, no clinical benefit was detected with minocycline in any of the primary and secondary clinical, neuroimaging and biochemical endpoints. Additionally, these RCTs primarily targeted to assess the safety of minocylcine and accordingly included lower hematoma volumes (mean 14.8 ml and 20.1 ml, respectively). This might have introduced type II error since minocycline would require substantial perihematomal volumes to demonstrate neuroprotection via MMP inhibition [27] . However, these RCTs coupled with the present meta-analysis highlight the safety of intravenous minocycline at doses as high as 10 mg/kg/day among patients with acute ICH. Future phase II RCTs will provide additional insights regarding the potential benefit of minocycline in hematoma expansion, PHE and functional improvement. Further, the safety of minocycline in ICH would permit its use in the prehospital setting, facilitating ultra-early treatment in the field by paramedics, potentially salvaging the penumbra for thrombolytic or endovascular treatment, and increasing the likelihood of functional recovery.
Our study has certain limitations that need to be acknowledged. First, the design of all included RCTs was open-label and this may have resulted in performance bias. Second, majority of the included RCTs were small and underpowered, and this could have introduced random error in our analyses. Third, heterogeneity in the majority of the included trials could have imposed further limitations. We attempted to address these methodological shortcomings by conducting sensitivity analyses separately in ischemic and hemorrhagic stroke patients. Additionally, we used random-effects model to assess the heterogeneity in our analyses. Fourth, the included RCTs evaluated heterogeneous doses and routes for minocycline administration that could have affected the pharmacokinetic profile, and thus may account for the heterogeneity documented in our meta-analysis. Finally, the variable therapeutic time window ranging between 6 and 24 h following symptom onset may represent another source of heterogeneity across the included studies.
In conclusion, our systematic review and meta-analysis consolidates all available clinical data on minocycline investigated in acute stroke patients. Although the data is limited, our results suggest minocycline as an efficacious and a safe agent in acute stroke patients. Our study underscores minocycline as a promising neuroprotective agent in AIS subgroup. Future adequately powered RCTs are warranted to establish the potential efficacy of minocycline separately in AIS and ICH subtypes.
